New Industries Require New Insight
The microbiome and its role in human health represents a paradigm shift in how medicines will be developed. The PRI was founded to make Microbiotic Medicinal Products a therapeutic reality in Europe.
A Unique Collaborative Approach
The PRI, as a neutral and financially independent non-profit association, applies a unique collaborative approach to improve market access and provide technical and regulatory intelligence for its members.
The Future of Human Health
The PRI believes that the microbiome is the future of human medicine. Our members have a stake in regulatory, technical and collaboration efforts of the microbiome & human health space.
Board of Directors
Board of Directors
Our Members
Start Ups
Biotechs
Investors
CROs
Research Institutions
LBP Developers
CDMOs
Pharma
Membership in the PRI plays an important role in several of our members’ development & marketing strategies.
Intelligence
Development Planning
Networking
Scientific Foresight
Investment
What are Microbiotic Medicinal Products (MMPs)?
The PRI defines MMPs as any medicinal product containing living, dead or fragments…, of components of the microbiome (i.e. bacteria, yeasts, phages, etc…) with the purpose to prevent or treat human diseases through a pharmacological, microbiological, neurological, immunological or metabolic mode of action, or make a medical diagnosis.
Non-Living Cells
Live Biotherapeutic Products
Faeces-derived Rx
Phage Therapy
Non-profit Association (loi 1901) | Europe’s first Microbiome Regulatory Science Expertise Center whose mission is to clarify and confirm the specific requirements for the development of microbiome-based medicinal products.
Expertise
Patients/Health
Medicine
Synergy
Find out more about the PRI from some of her members…
“…I am deeply convinced that if we grow our microbiotic medicinal products business, all companies and universities and academics should gather to create a new kind of offer to better treat patients.” Stanislas Desjonquères
“We had been thinking for sometime that the regulatory structure of probiotics was not satisfactory – probiotics had evolved from fermented foods – but really it fits more comfortably in the medicinal sector.” Peter Cartwright
“…for a Pharma company like Ferring, we really understand and think that next step will be developing Pharmabiotics in a true ‘Pharma’ way, and the PRI is in our opinion is the key partner and leader in Europe.” Jaimé Lopez
“The possibility to link up the academic world as well as the industry world in the PRI is really a very interesting option.” Bruno Pot
“…I’m really glad to be a part of these Task Groups – at the moment the PRI activities indeed for our company is something really relevant.” Marco Pané
“Probiotical has been with the PRI since the very beginning – and we’re very happy about our investment, as it is more and more important for developing Live Biotherapeutic Products.” Nina Vinot
“We are interested in the way the PRI is working with industrials, academics and Regulatory bodies to construct this market for pharmabiotics.” Etienne Nouguez
“…in fact the European aspect grew and grew for the PRI…an association that began with French roots has now become a truly European organization.” Massimo Marzorati
One-to-One Partnering
Microbiome dedicated one-to-one partnering forum. Schedule 20+ meetings with decision makers from Academia & Industry.
Conference
30+ presentations covering topics such as Cancer, Gut-Lung Axis, Urogenital as well as Regulatory Affairs and Market Trends.
Exhibition
Tailor suited solutions for your business needs. Promote your products and services to the Global Microbiome Community.
Innovation Showcase
Start-ups, spin-offs, academics & entrepreneurs present the latest innovations of microbiome products, services and research.